Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Primary Peritoneal Serous Adenocarcinoma”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Large-scale testing (Phase 3)Active Not RecruitingNCT02446600
What this trial is testing

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated Carcinoma+10 more
National Cancer Institute (NCI) 579
Early research (Phase 1)Study completedNCT01489371
What this trial is testing

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
Gynecologic Oncology Group 16
Early research (Phase 1)Active Not RecruitingNCT02142803
What this trial is testing

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Who this might be right for
Adult GlioblastomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+21 more
National Cancer Institute (NCI) 50
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Early research (Phase 1)Study completedNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Large-scale testing (Phase 3)Active Not RecruitingNCT02502266
What this trial is testing

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous Adenocarcinoma+12 more
National Cancer Institute (NCI) 582
Testing effectiveness (Phase 2)Active Not RecruitingNCT02345265
What this trial is testing

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Who this might be right for
Fallopian Tube CarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous Adenocarcinoma+6 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT02953457
What this trial is testing

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Serous Adenocarcinoma+3 more
Roswell Park Cancer Institute 40
Testing effectiveness (Phase 2)Study completedNCT00551070
What this trial is testing

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Who this might be right for
Borderline Ovarian Serous TumorLow Grade Ovarian Serous AdenocarcinomaMicropapillary Serous Carcinoma+3 more
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Study completedNCT02853318
What this trial is testing

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+11 more
Roswell Park Cancer Institute 40
Early research (Phase 1)Study completedNCT00002600
What this trial is testing

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)UnknownNCT06161272
What this trial is testing

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
Guangxi Medical University 80
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Early research (Phase 1)WithdrawnNCT02050009
What this trial is testing

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian Papillary Serous CarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube Cancer+3 more
Fox Chase Cancer Center
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 55
Early research (Phase 1)Active Not RecruitingNCT05527184
What this trial is testing

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Who this might be right for
Endometrial CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+2 more
AbbVie 256
Testing effectiveness (Phase 2)Study completedNCT00275028
What this trial is testing

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerPrimary Peritoneal Serous AdenocarcinomaRecurrent Ovarian Epithelial Cancer+2 more
National Cancer Institute (NCI) 47
Early research (Phase 1)Study completedNCT00652691
What this trial is testing

Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal Cavity Cancer
Mayo Clinic 48
Next Page